- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
In The Literature: MicroRNA Biomarkers Could Predict Chemotherapy Response in Lung Cancer
MicroRNAs have the potential to be predictive biomarkers that can predict survival as well as response to chemotherapy, as this study discovered.
Tumor samples from recurrent lung adenocarcinoma patients treated with platinum-based doublet chemotherapy were analyzed for microRNA expression. The analysis identified a signature: miR1290, miR196b, and miR135a*. These 3 microRNAs could predict chemotherapy response, not progression-free survival or overall survival, in patients with recurrent lung cancer.
Link to the abstract in Clinical Cancer Research: http://bit.ly/1m5Ed8v
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
